Trial Information

Summary: Evaluation of Molecular Abnormalities of Potential Relevance to the Efficacy of Targeted Anticancer Treatment in Lung and Head & Neck Cancers (EGFR)

Primary Objectives:

• To assess the time taken from sample receipt to availability of final tumor molecular abnormality lab data for each patient.
• To investigate the EGFR-gene mutations, EGFR- protein activation, and EGFRexpression in all patients with non-small cell lung cancer and head and neck cancer, undergoing surgical resection or diagnostic biopsy.

Secondary Objectives:

• To evaluate relationships between tumor molecular abnormalities and anti-tumor response rate to epidermal growth factor receptor tyrosine kinase inhibitors (EGFRTKI's); Iressa and Tarceva in patients with non-small cell lung cancer or head & neck cancer, in case that the blinded treating physician decide to treat the patients with EGFR-TKI's.
• To evaluate progression free survival and overall survival in patients mentioned above.

Patient Inclusion Criteria:

• At least 18 years old.
• Signed informed consent.
• All patients with non-small cell lung cancer or head & neck cancer.
• Evaluable disease.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:42:54 AM